Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Astal Laboratories has submitted copies of newspaper clippings as proof of publication of its unaudited standalone financial results for the quarter and half year ended September 30, 2025, in compliance with SEBI LODR Regulation 47. The results were published in The Financial Express (English) and Jansatta (Hindi) on November 16, and in Business Standard (English, Hyderabad) on November 17, 2025. For Q2 FY26, revenue from operations stood at Rs 3,751.64 lakhs (up from Rs 1,315.98 lakhs in Q2 FY25), with profit after tax of Rs 256.26 lakhs (vs Rs 200.29 lakhs YoY). For H1 FY26, revenue was Rs 6,284.30 lakhs vs Rs 2,063.55 lakhs in H1 FY25, a roughly 3x jump, while PAT rose to Rs 467.22 lakhs (vs Rs 369.20 lakhs). The results were approved by the Board on November 14, 2025.
This is a routine regulatory filing confirming public dissemination of already-disclosed Q2/H1 FY26 results. The underlying financials show strong top-line growth (~200% YoY for H1) but more moderate profit growth (~26% YoY), which may be of interest to investors tracking the small-cap stock.